[go: up one dir, main page]

EP1092019A1 - Homologue humain de la proteine unc-53 de c. elegans - Google Patents

Homologue humain de la proteine unc-53 de c. elegans

Info

Publication number
EP1092019A1
EP1092019A1 EP99926511A EP99926511A EP1092019A1 EP 1092019 A1 EP1092019 A1 EP 1092019A1 EP 99926511 A EP99926511 A EP 99926511A EP 99926511 A EP99926511 A EP 99926511A EP 1092019 A1 EP1092019 A1 EP 1092019A1
Authority
EP
European Patent Office
Prior art keywords
protein
unc
cell
compound
elegans
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99926511A
Other languages
German (de)
English (en)
Inventor
Walter Herman Maria L. Janssen Pharm. N.V. LUYTEN
Marc C. Janssen Pharmaceutica N.V. DE RAEYMAEKER
Johan Jozef Gustave H. Janssen Pharm. N.V. GEYSEN
Thierry A. O. E. Bogaert
Luc Jacques Simon Devgen N.V. MAERTENS
Peter Janssen Pharmaceutica N.V. VERHASSELT
Marc Devgen N.V. VAN DE CRAEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of EP1092019A1 publication Critical patent/EP1092019A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to a vertebrate homologue of UNC-53 protein of C. elecrans and cDNA sequences coding for said homologues or functional equivalents thereof.
  • the invention also relates to processes for identifying compounds which control cell behaviour, compounds identified and pharmaceutical compositions containing them in addition to processes and assays for identifying disease states in which said gene or protein is dysfunctional.
  • control of cell motility, cell shape and directionality of cell outgrowth of axones or other cell outgrowths is an essential feature in the morphogenesis and function of both unicellular and multicellular organisms.
  • a long-range migration of a cell process (also known as a growth cone extension) is a stepwise event, whereby prior to and after each extension there is the formation of a structure at the leading edge of the cell.
  • Localised stabilisation of the actin cytoskeleton and association with plus end regions of microtubules is a general cell biological process underlying the choice of directional extension.
  • the present inventors have surprisingly found a new human gene/protein belonging to the UNC-53 family that binds microtubules and, in particular, the plus- end regions of microtubules.
  • a gene from the free-living nematode is a gene from the free-living nematode
  • hs-unc-53/3 shows homology to the cortical actin binding proteins, and the Ce-UNC-53 protein has been shown to bind F-actin in vitro and leads to actin re-organization in vivo when expressed in mammalian cells, leading to an increased number of filopodia and lammelipodia.
  • Hs-UNC-53-3 may play an important role in the development of various diseases .
  • a vertebrate protein homologue of an UNC-53 protein of C. elegans which protein comprises an amino acid sequence having one or more of sequence blocks A, B, C, D, E, F, G or H as illustrated in figure 4 or which differs from said blocks in conservative amino acid changes.
  • a "derivative" should be taken to mean mutational derivatives, fusions, internal deletions, splice variants and muteins.
  • said vertebrate homologue is a human protein, and preferably a mammalian or a mouse protein.
  • a further aspect of the invention comprises a vertebrate homologue comprising an amino acid sequence as shown in figure 1(f) or the variants thereof or an amino acid sequence which differs from the amino acid sequences shown in figure 1(f) to a significant extent only in one or more conservative amino acid changes.
  • a nucleic acid molecule which is preferably DNA, and which encodes a vertebrate homologue of UNC-53 protein of C. elegans, or a functional equivalent derivative, fragment or bioprecursor of said homologue according to the invention.
  • the cDNA comprises a sequence of nucleotides encoding an amino acid sequence as illustrated in figure 1(f) or the variants thereof or an amino acid which differs from the sequences shown in these figures to a significant extent only in one or more conservative amino acid changes.
  • the DNA is cDNA, which cDNA comprises the sequence shown in figure 1(e) or the variants indicated therein.
  • a nucleic acid sequence capable of hybridising to the nucleic acid or DNA sequences according to the invention under high stringency conditions, which conditions are well known to those skilled in the art.
  • the cDNA according to the invention may be included in an expression vector which may itself be used to transform or transfect a host cell, which cell may be bacterial or eukaryotic in origin including such as, for example an animal or plant cell a fungal cell or an insect cell.
  • a host cell which cell may be bacterial or eukaryotic in origin including such as, for example an animal or plant cell a fungal cell or an insect cell.
  • a range of cells, tissues or organisms may be transfected following incorporation of the selected cDNA clone into an appropriate expression vector.
  • the expression vector according to the invention may comprise a promoter of C. elegans or one of human, mouse or viral origin and optionally a sequence encoding a reporter molecule, such as, for example, green fluorescent protein.
  • the present invention therefore, also further comprises a transgenic cell, tissue or organism comprising a transgene capable of expressing a vertebrate homologue of UNC-53 protein of C. elegans according to the invention.
  • transgene capable of expressing a vertebrate homologue of UNC-53 protein of C. elegans means a suitable nucleic acid sequence which leads to the expression of a vertebrate homologue of UNC-53 protein of C. elegans according to the invention having the same function and/or activity.
  • the transgene may include, for example, genomic nucleic acid isolated from the appropriate vertebrate or synthetic nucleic acid including cDNA.
  • transgenic organisms, tissues or cells, as used herein means any suitable organism and/or part of an organism, tissue or cell, that contains exogenous nucleic acid either stably integrated in the genome or in an extrachromosomal state.
  • the transgenic cell comprises any of, a COS cell, HepG2 cell, MCF-7 or N4 neuroblastoma cell, a NIH3T3 cell, a colorectal or carcinoma cell or a human derived cell such as a fibroblast or the like.
  • the transgenic organism may be an insect, a non-human animal or a plant and preferably C. elegans or a related nematode.
  • the transgene comprises the nucleic acid or cDNA sequence encoding the vertebrate homologue according to the invention as described above.
  • the transgene preferably comprises an expression vector according to the invention.
  • the term "functional fragment” as used herein should be taken to mean a fragment of the gene coding for the vertebrate homologue of the UNC-53 protein of C. elegans according to the invention.
  • the gene may comprise deletions or mutations but may still encode a functional vertebrate homologue of UNC- 53 protein.
  • mutant vertebrate non-human organism having a mutation in the wild-type gene coding for the vertebrate homologue of UNC-53 protein according to the invention, which mutation affects cell behaviour or the regulation of cell motility or the shape or the direction of cell migration or microtubule plus end stability or function and localisation of protein complexes located thereon, which method comprises inducing a mutation in the vertebrate homologue of UNC-53 protein in said organism.
  • mutant organisms may be used in a screen to identify the effects of compounds on these cell functions.
  • the vertebrate homologue of UNC-53 protein of C. elegans or the cDNA or genomic DNA encoding it or a functional equivalent, derivative, fragment or bioprecursor of said homologue may advantageously be used as a medicament, or in the preparation of a medicament to treat or prevent disorders associated with inhibition of overexpression of the vertebrate homologue of UNC -53 according to the invention.
  • disorders may be alleviated by promoting neuronal regeneration, revascularisation or wound healing or the treatment of chronic neurodegenerative disorders, psychiatric disorders or acute traumatic injuries or fibrotic disease or disease in which physiological events requiring the polarity of cells or epithelia are abnormally functioning.
  • the vertebrate homologue according to the invention may advantageously be used to induce or alleviate contact inhibition in a cell or in preventing carcinoma development.
  • the above medical conditions may be treated in mammals and more preferably humans by either the homologue of UNC- 53 protein or alternatively by a nucleic acid coding for the protein or the protein itself according to the invention.
  • an antisense oligonucleotide to said UNC-53 vertebrate homologue may be used to prevent it's expression.
  • nucleic acid sequences which may be used include 3' untranslated regions of mRNA which could be used to prevent transcription of the genomic sequence encoding for the vertebrate homologue of UNC-53 protein according to the invention.
  • the vertebrate homologue of UNC-53 protein according to the invention may be incorporated into a pharmaceutically acceptable composition together with a suitable carrier, diluent or excipient therefor.
  • the pharmaceutical composition may advantageously comprise, additionally or alternatively, the nucleic acid sequence according to the invention as defined above .
  • the induction or inhibition of the expression of hu-UNC-53/3 by pharmacological means may advantageously be used to induce neuronal regeneration, revascularisation or wound healing or be involved in the treatment of chronical neurodegenerative disorders, or acute traumatic injuries or fibrotic diseases, or physiological events requiring the polarity of cells, or oncology and metastasis of cells, or apoptotic pathways.
  • the present invention therefore also provides for a method of determining whether a compound is an inhibitor or enhancer of the regulation of cell behaviour, growth, transformation, cell shape or motility or the direction of cell migration, microtubule plus end stability or function and localisation of protein complexes thereon, which method comprises contacting said compound with a transgenic cell according to the invention and screening for a phenotypic change in said cell.
  • the method can therefore be used to determine whether the compound comprises an inhibitor or an enhancer of the signal transduction pathway of said transgenic cell of which pathway said vertebrate homologue of UNC-53 protein according to the invention is a component, or whether said compound is an inhibitor or an enhancer of a parallel or redundant signal transduction pathway in said cell.
  • the present invention also provides a method to determine that the protein in said signal transduction pathway is a vertebrate homologue of UNC- 53 protein of C. elegans according to the invention.
  • the phenotypic change to be screened comprises a change in cell shape or a change in cell motility.
  • a transgenic cell is used in accordance with one embodiment of the method of the invention, an N4 neuroblastoma cell may be used and in such an embodiment the phenotypic change to be screened may be the length of neurite growth, changes in filopodia outgrowth, changes in ruffling behaviour or cell adhesion, any change in microtubule cytoskeleton, any change in localisation of proteins on plus end regions of microtubules or any change in a cell such as apoptosis.
  • the transgenic cell may comprise an MCF-7 breast carcinoma cell.
  • the phenotypic change to be screened comprises the extent of phagokinesis or filopodia formation.
  • the transgenic cell may comprise an NIH3T3 cell.
  • the phenotypic change to be screened comprises loss of contact inhibition of foci formation.
  • the method according to the invention may also utilise a mutant cell or mutant organism according to the invention as described above, where the mutant cell is capable of growing in tissue culture or in vivo and either of which cell or organism has a mutation in the wild-type unc-53 gene.
  • a "phenotypic change” may comprise any phenotype resulting from changes at any suitable point in the life cycle of the cell, tissue or organism defined above, which change can be attributed to the expression of the transgene of the invention such as for example, growth, viability, morphology, behaviour, movement, cell migration or cell process or growth cone extension of cells and includes changes in body shape, locomotion, chemotaxis, contact inhibition, mating behaviour or the like.
  • the phenotypic change may preferably be monitored directly by visual inspection of the cell as a whole or by monitoring the F-actin cytoskeleton microtubule network and plus end stability of microtubules or proteins thereon or alternatively by for example measuring indicators of viability including endogenous or transgenically introduced histochemical markers or other reporter genes, such as for example ⁇ -galactosidase or green fluorescent protein.
  • a compound which is identifiable by the method according to the invention as described above, as an enhancer of the processes identified above such as the regulation of cell shape or motility or the direction of cell migration may be used as a medicament, or alternatively in the preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro- degenerative diseases or acute traumatic injuries or fibrotic disease.
  • Examples of promoting neuronal regeneration include, for example, peripheral nerve regeneration after trauma and spinal cord trauma.
  • the compound may be used as a medicament, or in the preparation of a medicament, for substantially alleviating spread of disease inducing cells, such as in spread of carcinoma, or the like in metastasis or in alleviating loss of contact inhibition.
  • any of the compounds which may have been identified as an inhibitor or an enhancer in accordance with the method as described above may also be included in a pharmaceutical composition comprising the respective compound and a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • a compound identified as either an inhibitor or an enhancer of the cell motility shape, growth or direction of cell migration or microtubule association or to the plus end region thereof is not limiting.
  • the compound acts as an inhibitor or enhancer of a signal transduction pathway.
  • the compound may also act on a parallel pathway or directly on the vertebrate homologue of UNC-53 protein of C. elegans.
  • the method of action of the compound may include direct interaction with the vertebrate homologue of UNC-53 protein, interaction with processes for regulating phosphorylation or dephosphorylation of the vertebrate homologue of UNC- 53 or with processes regulating activity of an unc-53 gene or with processes for post-transcriptional or post-translational modification or the like.
  • the compound is identified by the method according to the invention as an inhibitor or an enhancer, by utilising differences of phenotype of the cell, tissue or organism, which are visible to the eye.
  • indicators of viability including endogenous or transgenically introduced histochemical markers or a reporter gene may be used.
  • a transgenic cell or tissue culture which has been constructed to comprise a promoter sequence of a gene coding for a vertebrate homologue of UNC-53 of C. elegans according to the invention operably linked to a nucleic acid sequence encoding a reporter molecule.
  • the reporter sequence encodes for a detectable protein, for example one which may be monitored by eye inspection such as antibiotic resistance, ⁇ - galactosidase or a molecule detectable by spectrophotometric, spectrofluorometric, luminescent or radioactive assays.
  • a detectable protein for example one which may be monitored by eye inspection such as antibiotic resistance, ⁇ - galactosidase or a molecule detectable by spectrophotometric, spectrofluorometric, luminescent or radioactive assays.
  • the present invention also provides a method of determining whether a compound is an inhibitor or an enhancer of transcription of a gene coding for a vertebrate homologue of UNC-53 protein in C. elegans, according to the invention which method comprises the steps of:
  • the reporter molecule may comprise messenger RNA.
  • a compound identified as an enhancer of transcription of the gene coding for the vertebrate homologue of UNC-53 protein of C. elegans or a functional equivalent, derivative or bioprecursor of said homologue may also be used as a medicament, or in the preparation of a medicament, for promoting neuronal regeneration, revascularisation or wound healing, or for treatment of chronic neuro- degenerative diseases or acute traumatic injuries or fibrotic disease.
  • such compounds may be included in a pharmaceutical composition including a pharmaceutically acceptable carrier, diluent or excipient therefor. Any compounds identified as inhibitors of transcription may, advantageously, be used in alleviating the spread of disease inducing cells such as carcinomas or metastasis or loss of contact inhibition.
  • the present invention also provides a kit for determining whether a compound is an enhancer or an inhibitor of the regulation of cell growth, transformation, cell motility or shape or the direction of cell migration which kit comprises at least one transgenic or mutant cell or transgenic or mutant non-human organism according to the invention as described above and a plurality of wild-type cells or a wild-type organism of the same type, or a cell line or tissue culture and means for contacting said compound with said cell or organism.
  • kits for determining whether a compound is an inhibitor or an enhancer of transcription of a gene coding for a vertebrate homologue of UNC-53 protein of C. elegans according to the invention which kit comprises at least one transgenic cell or cells according to the invention, means for contacting said compounds with said cells and means for monitoring the level of transcription of said transgenic cell or cells according to the invention.
  • the term "gene coding for a vertebrate homologue of UNC-53 or a functional fragment of said homologue” includes the nucleic acid sequence shown in figure 1 or a fragment thereof, including the differentially spliced isoforms and transcriptional starts of the nucleic acid sequence and which sequence encodes a vertebrate homologue of UNC-53 protein or a functional equivalent, derivative, fragment or bioprecursor of the protein.
  • the present invention also provides methods of identifying genes of vertebrates or fragments of said genes, which encode proteins which are active in the signal transduction pathway of which the vertebrate homologue of UNC-53 according to the present invention is a component.
  • a preferred method comprises hybridizing to an appropriate cDNA library a nucleotide sequence, as defined herein, or a fragment thereof under appropriate conditions of stringency in order to identify genes having statistically significant homology with the cDNA clones of any one of the cDNA sequences according to the invention described above.
  • a method of identifying a protein which is active in the signal transduction pathway of a cell of which a vertebrate homologue of UNC-53 protein of C. elegans according to the invention is a component. According to this aspect of the invention, the method comprises;
  • the vertebrate homologue of UNC-53 protein therefore may bind regions of other proteins involved in the signal transduction pathway. It is also possible to sequentially identify a whole range of proteins involved in the signal transduction pathway.
  • Antibodies to the vertebrate homologue of UNC-53 protein may be produced according to known techniques as would be known to those skilled in the art. For example, polyclonal antibodies may be prepared by inoculating a host animal, such as a mouse, with a protein or epitope of a protein according to the invention and recovering immune serum.
  • This aspect of the invention further comprises a method of identifying a further protein or proteins which are active in the signal transduction pathway of a cell of which the vertebrate homologue of UNC-53 is a component which method comprises:
  • the antibody starts the process by binding to the vertebrate homologue of UNC-53 protein according to the invention in the signal transduction or oncogenic pathways. Any other proteins found complexed to the bound antibody or UNC-53 protein can then be used to identify further interacting proteins involved in the pathway.
  • the method comprises:
  • UNC-53 protein other than the same vertebrate homologue of UNC-53 protein.
  • This method can also advantageously be used to identify further proteins in a signal transduction pathway of a cell by contacting an extract of the cell used as described above, with any protein identified from step (c) above not being a vertebrate homologue of UNC-53 protein and repeating steps (b) and (c) .
  • a western blot overlay method which method is well known to those skilled in the art.
  • Cell extracts are run on gels to separate out protein and subsequently blotted onto a nylon membrane. These membranes may then be incubated, for example in a medium containing vertebrate homologue of UNC-53 having a label attached thereto such as a biotin or radiolabel and any protein conjugates visualised with for example a streptavidin or alkaline phosphatase conjugated antibody.
  • the present invention also advantageously provides a process for the preparation of binding antibodies which recognise proteins or fragments thereof involved in the rate and direction of cell migration or the control of cell growth or shape, for the above methods .
  • the monoclonal antibody for binding to the appropriate vertebrate homologue of UNC-53 may be prepared by known techniques as described by Kohler R. and Milstein C, (1975) Nature 256, 495 to 497.
  • Another method which may be used to identify proteins involved in the signal transduction pathway of a cell of which a vertebrate homologue of an UNC-53 protein of C. elegans according to the invention or is a component, involves investigating protein-protein interactions using the two-hybrid vector method.
  • This technique is based on functional reconstruction in vivo of a transcription factor which activates a reporter gene. More particularly the technique comprises providing an appropriate host cell with a DNA construct comprising a reporter gene under the control of a promoter regulated by a transcription factor having a DNA binding domain and an activating domain, expressing in the host cell a first hybrid DNA sequence encoding a first fusion of a fragment or all of a nucleic acid sequence according to the invention and either said DNA binding domain or said activating domain of the transcription factor, expressing in the host at least one second hybrid DNA sequence, such as a library or the like, encoding putative binding proteins to be investigated together with the DNA binding or activating domain of the transcription factor which is not incorporated in the first fusion; detecting any binding of the proteins to be investigated with a protein according to the invention by detecting for the presence of any reporter gene product in the host cell; optionally isolating second hybrid
  • GAL4 is a transcriptional activator of galactose metabolism in yeast and has a separate domain for binding to activators upstream of the galactose metabolising genes as well as a protein binding domain.
  • Nucleotide vectors may be constructed, one of which comprises the nucleotide residues encoding the DNA binding domain of GAL4.
  • binding domain residues may be fused to a known protein encoding sequence, such as for example a sequence coding for the vertebrate homologue of UNC-53.
  • the other vector comprises the residues encoding the protein binding domain of GAL4.
  • residues are fused to residues encoding a test protein, preferably from the signal transduction pathway of the vertebrate in question. Any interaction between the vertebrate homologue of UNC-53 protein and the protein to be tested leads to transcriptional activation of a reporter molecule in a GAL-4 transcription deficient yeast cell into which the vectors have been transformed.
  • a reporter molecule such as ⁇ -galactosidase is activated upon restoration of transcription of the yeast galactose metabolism genes.
  • Any proteins identified in the signal transduction pathway of the cell which may be for example a mammalian cell, may also be included in a pharmaceutical composition together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • the present invention also provides a process for producing a vertebrate homologue of an UNC-53 protein of C. elegans according to the invention which process comprises culturing the cells transformed or transfected with a cDNA expression vector having any of the cDNA sequences according to the invention as described above, and recovering the expressed protein homologue.
  • the cell may advantageously be a bacterial, animal, insect or plant cell.
  • a particularly preferred process for producing said vertebrate homologue of UNC-53 protein uses insect cells.
  • the invention provides a process for producing a vertebrate homologue of UNC-53 protein of C. elegans according to the invention which process comprises culturing an insect cell transformed or transfected with a recombinant Baculovirus vector, said vector comprising a nucleotide sequence encoding said vertebrate homologue of UNC-53 protein according to the invention downstream of the Baculovirus polyhedrin promoter and recovering the expressed protein.
  • this method produces large amounts of protein for recovery.
  • the insect cell may be from for example Spodoptera frugiperda or Drosophila Melanogester .
  • nucleic acid sequence includes not only the identical nucleic acid but also any minor base variations from the natural nucleic acid sequence including in particular, substitutions in bases which result in a synonymous codon (a different codon specifying the same amino acid) , due to the degenerate code in conservative amino acid substitution.
  • nucleic acid sequence also includes the complimentary sequence to any single stranded sequence given which includes the definition above regarding base variations.
  • a defined protein, polypeptide or amino acid sequence according to the invention includes not only the identical amino acid sequence but also minor amino acid variations from the natural amino acid sequence including conservative amino acid replacements (a replacement by an amino acid that is related in its side chains) . Also included are amino acid sequences which vary from the natural amino acid but result in a polypeptide which is immunologically identical or similar to the polypeptide encoded by the naturally occurring sequence. Such polypeptides may be encoded by a corresponding nucleic acid sequence.
  • a further aspect of the invention provides a nucleic acid sequence of at least 15 nucleotides of a nucleic acid according to the invention and preferably from 15 to 50 nucleotides.
  • nucleic acid sequences may, advantageously be used as probes or primers to initiate replication or the like.
  • Such nucleic acid sequences may be produced according to techniques well known in the art, such as by recombinant or synthetic means. They may also be used in diagnostic kits or the like for detecting for the presence of a nucleic acid according to the invention. These test generally comprise contacting the probe with a sample under hybridising conditions and detecting for the presence of any duplex formation between the probe and any nucleic acid in the sample.
  • Nucleic acid sequences according to the invention may also be produced using recombinant or synthetic means such as described in Sambrook et al (Molecular Cloning: A Laboratory Manual, 1989) .
  • human allelic variants or polymorphisms of the DNA according to the invention may be identified by, for example, probing DNA from a range of individuals for example from different populations.
  • nucleic acids and probes according to the invention may be used to sequence genomic DNA from patients using techniques well known in the art, such as the Sanger Dideoxy chain termination method, which may advantageously ascertain any predisposition of a patient to certain disorders.
  • a method of detecting whether a compound is an inhibitor or an enhancer or expression of a vertebrate homologue of UNC-53 of C. elegans, according to the invention comprises contacting a cell expressing said homologue with said compound and monitoring for a phenotypic change compared to a control cell which has not been contacted with said compound.
  • the cell is a transgenic cell as described above.
  • the cell may have undergone loss of contact inhibition.
  • the present method also provides for determining whether said compound is an inhibitor or expression of said vertebrate homologue.
  • the compound to be tested comprises a nucleic acid.
  • nucleic acid sequence comprises an antisense DNA sequence or a mRNA sequence.
  • said mRNA sequence comprises 3' untranslated regions of mRNA encoding for said vertebrate homologue.
  • the compound to be tested may be a protein.
  • said protein comprises a protein having an amino acid sequence potentially suitable for inhibiting function of said vertebrate homologue and preferably comprises a protein identified by the methods as described herein.
  • the present invention also provides a pharmaceutical composition
  • a pharmaceutical composition comprising a compound, for example an antisense nucleic acid identified according to the above described method together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • a nucleic acid sequence or protein identified according to this aspect of the invention may be used as a medicament, or in the preparation of a medicament, for treating loss of contact inhibition of cancer which is mediated by vertebrate homologue of UNC-53 protein or a functional equivalent, fragment, derivative or bioprecursor of said homologue.
  • nucleic acid as defined above for use in preparation of a medicament for inhibiting expression of a gene coding for a vertebrate homologue of UNC-53 protein of C. elegans.
  • an assay for detecting expression of the vertebrate homologue of UNC-53 protein of C. elegans in a vertebrate cell comprises contacting a cell or an extract thereof with an antibody to said vertebrate homologue, which antibody is fused to a reporter molecule, removing any unbound antibody and monitoring for the presence of said reporter molecule.
  • the reporter molecule is an antibody conjugated to for example a fluorophore such as fluorescein or alternatively to an enzyme such as strepavidin.
  • a method for detecting for expression of a gene coding for the vertebrate homologue of UNC-53 protein of the invention comprises contacting a probe specific for a nucleic acid of protein sequence coding for or corresponding to said vertebrate homologue according to the invention with a cell extract, which probe is linked to a reporter and analysing for the presence of said reporter.
  • the probe is a complementary sequence to a region of mRNA transcribed from said gene encoding said vertebrate homologue of UNC-53 protein according to the invention.
  • the complimentary sequence is a 3' or 5' untranslated region of said mRNA.
  • said reporter may be a dig label, a fluorophore, a hapten or a radiolabel.
  • said probe may comprise an antibody specific for said vertebrate homologue of said UNC-53 protein.
  • the reporter is an antibody conjugated to for example a fluorophore such as fluorescein or alternatively an enzyme such as streptavidin.
  • UNC-53 protein of C. elegans has been found to localise to microtubule and particularly to microtubule (+) ends. Therefore, there is provided by a further aspect of the present invention a method of determining whether a compound is an inhibitor or an enhancer of association of the UNC-53 homologue of the invention to microtubules or plus end regions thereof, which method comprises (a) contacting said compound with a transgenic cell, tissue or organism expressing said vertebrate homologue and which protein is operably linked to a reporter molecule (b) screening for the localisation of said reporter molecule as compared to a cell according to step (a) which has not been contacted with said compound.
  • a compound identifiable by the above method also forms part of the present invention.
  • Such a compound identified as an inhibitor of localisation or association of said vertebrate homologue with microtubules or the plus end region thereof may be used in alleviating the spread of disease inducing cells or metastasis or loss of contact inhibition.
  • a compound identified as an enhancer of association of said vertebrate homologue with microtubules or the plus end region thereof may be used in for example promoting neuronal regeneration, revascularisation or wound healing, or for treating chronic neurodegenerative diseases or acute traumatic injuries or fibrotic disease.
  • These compounds may then be included in a pharmaceutical composition, together with a pharmaceutically acceptable carrier, diluent or excipient therefor.
  • kits for determining whether a compound is an inhibitor or an enhancer of association of the vertebrate homologue thereof according to the invention with microtubules or the plus end regions thereof which kit comprises at least one transgenic cell expressing said UNC-53 vertebrate protein homologue and a reporter molecule or a host or transgenic cell according to the invention and at least one cell of the same cell type for use as a control and means for contacting said compound with one of said at least one transgenic cells.
  • Compounds identified as inhibitors or enhancers or microtubule association described above may advantageously be included in a composition and linked to said vertebrate homologue according to the invention to target the compounds to the microtubules or the plus end regions thereof.
  • Such a composition may also comprise, for example, a suitable transfecting or transformation agent.
  • a method of targeting a protein to a cell microtubule or the plus end region thereof comprises introducing into a host cell, tissue or organism a transgene comprising a sequence capable of expressing said UNC-53 vertebrate homologue according to the invention, which sequence is operably linked to a sequence encoding said protein to be targeted such that a chimeric protein is expressed and which results in targeting of said protein to said microtubule or a plus end region thereof.
  • An even further aspect of the invention comprises a method of identifying a molecule which covalently modifies UNC- said vertebrate homologue according to the invention, which method comprises a) contacting either an extract from a cell or cells expressing said vertebrate homologue or a mixture of enzymes comprising candidate UNC-53 modifying enzymes in the presence of an indicator of covalent modification of a protein, b) identifying any covalently modified UNC-53 protein from step a) and c) identifying said molecule involved in said modification step.
  • an indicator may be 32 P.
  • the invention is a method of identifying a compound which alleviates or enhances the toxicity of said UNC-53 vertebrate homologue thereof according to the invention, or which alleviates or enhances apoptosis.
  • the method of the former comprises contacting said compound with a transgenic cell, tissue or organism according to the invention and monitoring for the presence of said reporter molecule adjacent said microtubules or the plus end region thereof.
  • the method comprises monitoring the effect of the compound on cell death.
  • Figure 1(a) is an illustration of the nucleotide sequence encoding the first human homologue of UNC-53 designated Hs-UNC-53/1 and further variants thereof.
  • Figure 1 (b) is an illustration of the amino acid sequence of hs-UNC-53/1 encoded by the sequences in Figure 1 (a) .
  • Figure 1(c) is an illustration of the nucleotide sequence encoding the second human homologue of UNC-53 protein of C. elegans designated Hs-UNC-53/2 and further variants thereof.
  • Figure 1 (d) is an illustration of the amino acid sequences of Hs-UNC-53/2 encoded by the sequences in Figure 1(c).
  • Figure 1 (e) is an illustration of a nucleotide sequence encoding the third human homologue of UNC-53 protein according to the invention designated Hs-UNC- 53/3, and variants thereof.
  • Figure 1(f) is an illustration of the amino acid sequences of the Hs-UNC-53/3 encoded by the sequences of Figure 1 (e) .
  • Figure 1(g) is an illustration of the nucleotide sequence of a genomic DNA fragment that contains a putative 5' exon of Hs-unc-53/1.
  • Figure 1 (h) is an illustration of the nucleotide sequence AB023155 encoding the protein KIAA0938, a transcript comprising the 3' half of Hs-unc-53/3.
  • Figure l(i) is an overview of the C. elegans and human UNC-53 proteins as cloned. The 5' truncated variants and a number of the known splice variants have been indicated.
  • Figure 2 is an alignment of the amino acid sequences of Ce-UNC-53, Hs-UNC-53/1 , Hs-UNC-53/2 and Hs-UNC-53/3.
  • Figure 3 is an alignment of the C. elegans unc-53 and the predicted amino acid sequence of C. briggsiae unc-53.
  • Figure 4 is a list of ProSite signatures for vertebrate UNC-53s based on the sequence alignment.
  • Figure 5a is an illustration of expression of the three human UNC-53s as studied by Northern blotting.
  • Figure 5(b) is an illustration of differential expression of Hs-unc-53/3 in different brain parts.
  • Figure 6(a) is an illustration of differential splice variant expression of Hs-unc-53/1 using RT-PCR.
  • Figure 6(b) is an illustration of differential splice expression of Hs-unc-53/2 using RT-PCR.
  • Figure 6(c) is an illustration of differential expression of Hs-unc-53/3 using RT-PCR.
  • Figure 6(d) is a sequence confirmation of AB023155 expression in cells other than brain using RT-PCR.
  • Figure 7(a) is an illustration of the cloning of Hs-unc-53/3.
  • Figure 7 (b) is a plasmid map and the nucleotide sequence of the pGI3303 expression vector ( C-terminal Hs-unc-53/3 fragment in fusion with GFP) .
  • Figure 7(c) is an illustration of the amino acid sequence of GFP: C-terminal Hs-unc-53/3 fragment (insert of pGI3303) .
  • Figure 7 (d) is a plasmid map and the nucleotide sequence of the pGI3305 expression vector (full length Hs-unc-53/3 in fusion with GFP) .
  • Figure 7 (e) is an illustration of the amino acid sequence of GFP : Hs-unc-53/3 (insert of pGI3305) .
  • Figue 8 is an illustration of the filipodia and lamellipodia outgrowth of N4 mouse neuroblastoma cells transfected with pGI3303 (F-actin cytoskeleton reorganisation)
  • Figure 9 is an illustration of the co- localisation of the GFP:Hs-unc-53/3 fusion protein with microtubules in N4 mouse neuroblastoma cells transfected with pGI3305.
  • Figure 11a is an illustration of the homology domains between Hs-unc-53/3 and a gene encoded (partially) by the Drosophilia melanogaster BAC clone BACR48M05 (AC005719) . Results of a TBLASTN search on the non-redundant database with Hs-unc-53/3 as query.
  • Figure lib is an illustration of an ORF encoded by the Drosophila melanogaster BAC clone BACR48M05 (AC005719) as predicted by the computer program Fgene.
  • Figure lie is an illustration of a "BLAST 2 sequences" search result with Hs-unc-53/3 as query and the Fgene predicted UNC53 homology ORF of D. melanogaster BAC clone BACR48M05.
  • Figure 12 is an illustration of a zebra fish EST encoding Dr-unc-53/2.
  • Figure 14 is a schematical drawing of the sequence of the exon containing the putative alternative start codon of human Hs-unc-53/1.
  • Figure 15 is an illustration of the nucleotide sequence of pGI3150 and the amino acid sequence of the eGFP fusion with a C-terminal fragment of Hs-Unc-53/1.
  • Figure 16 is an alignment of EST clone yk480b6 and Ce-unc-53 demonstrating a novel splice variant of Ce-unc-53.
  • Figure 17 is a graphical display of the effect of Hs-unc-53/3 GFP chimera transient transfection on the form factor of N4 cells.
  • Plasmids pG13303 and pG13305 were deposited under accession numbers LMBP3936 and LMBP3937 respectively on 28 May 1999 at the Belgian Coordinated Collections of Microorganisms (BCCM) at Laboratorium voor Moleisme Biologie - Plasmidencollective (LMBP) B- 9000 Ghent, Belgium, in accordance with the provisions of the Budapest Treaty of April 28 1977.
  • Hs-UNC-53/3 is a bona fide UNC-53 (fig. 1; 2; 3)
  • Hu-UNC- 53/3 most likely has the key functionalities observed for Ce-UNC-53 in a variety of assays including F-actin binding, F-actin reorganisation in cell culture, microtubule and microtubule (+)-end binding in cultured cells, binding of SH3-domain adapters like
  • the C. elegans genome consortium sequenced the locus of the C. briggsiae unc-53 homologous gene. Through gene prediction programs and the cDNA sequence of the C. elegans unc-53, prediction can be made for the C. briggsiae protein sequence. Alignment of the derived C. briggsiae amino acid sequence with the C. elegans amino acid sequence in figure 3 demonstrates the strong homology of both proteins.
  • BAC clone BACR48M05 (AC005719) clearly contains 3 different exons with high homology to Hs-unc-53/3 ( Figure 11) .
  • Fgene Solovyev et al., 1995, in: Proceedings of the Third International Conference on Intelligent Systems for Molecular Biology (eds. Rawling et al., Cambridge, England, AAAI Press) ; Solovyev and
  • the predicted ORF of the Drosophila melanogaster UNC53 gene can be used to identify new members of the family.
  • the zebrafish EST fc21d06 shows an identity of 84% and a homology of 92% to Hs-UNC-53/2. It clearly can be considered as a part of the zebrafish homologue of Hs- UNC-53/2 ( Figure 12) .
  • a whole series of human ESTs have been placed in public domain databases. To our knowledge, no one has been able to place these ESTs into contigs that describe a true Hs- unc-53 to a level presented in this specification.
  • the presently available unc-53 sequences - expressed or genomic - further underscore that the unc-53 gene family is a true animal gene family in helminths, vertebrates and arthropods, three major classes of the animal kingdom.
  • a Northern blot of poly-A+RNA from several cancer cell lines was probed using the whole insert of pHH3b. No or weak expression was detected in the Burkitt Lymphoma DRajii, the Leukemia Molt4 and the Promyelocytic Leukemia HL60 cell lines.
  • transcripts 1 and 2 are larger than 9.5kb
  • transcripts 3 and 4 are 6 to 7 kb
  • the fifth transcript is around 6 kb.
  • Transcripts 1 and 2 are present in all expressing cell lines but at different levels.
  • Transcripts 3 and 4 are restricted to Melanoma G361, Lung Cancer A549 (weak) and Colorectal Adenocarcinoma SW480 and are the predominant transcripts in Melanoma G361 and Colorectal Adenocarcinoma SW480.
  • Transcript 5 is restricted to Lymphoblastic Leukemia K562 (weak) and (predominant) in HeLa S3 and is predominant in HeLa S3.
  • Hs-UNC53/2 Normal Human tissue probed with Hs-UNC53/2.
  • a similar set of blots were probed with a 652bp fragment of EST46037 amplified by using the primers 5' aggagatgaagctgacagatatcc and 5'- aaacaccagtgagtcc.
  • Expression levels are low in all tissues with the highest level in kidney, placenta and pancreas, lower levels in heart and lung. Expression is barely detectable or undetectable in skeletal muscle, spleen, thymus, prostate, testis, ovary, small intestine, colon peripheral blood leucocyte, stomach, thyroid, spinal cord, trachea, adrenal gland and bone marrow.
  • Hs-unc-53/2 appears to be expressed as different transcripts (figure 5a).
  • hs-UNC53/l and hs-UNC-53/2 homologues are clearly highly regulated genes, showing a strong tissue specificity and, probably, additional mechanisms of regulation (ie differential splicing of different promoters) .
  • the different proteins derived from RNA' s identified by probe hhl5 presumably share the carboxyterminal nucleotide binding domain.
  • Ce-UNC-53 was shown to be a complex genetic locus and complex transcription unit.
  • the different transcripts are thought to be a mechanism to assure the necessary specificity and functional diversity of this signal transduction pathway, with respect to different signals and receptors, different tissues and different directions of migration.
  • the occurrence of a new transcript or the observed changes in expression levels in the cancer cell line blot suggests a role for hs-UNC-53/3 in the establishment or maintenance of the transformed state of those cells. Expression pattern of hs-UNC-53/3.
  • Hs-unc-53/3 has a high expression level in lung carcinoma line A549, where only a moderate expression of hs-unc-53/1 has been detected. Furthermore, moderate expression of Hs-unc-53/3 was also observed in melanoma line G361, where previously, a high expression of hs-UNC-53/1 and hs-UNC-52/2 has been observed. This indicated the involvement of hs-unc53/3 in at least two cancer lines .
  • Hs-unc-53/3 shows a clearly new and previously unobserved expression pattern. This difference of expression of hs-unc-53/3 in relation to its homologues hs-unc53/l and hs-unc53/2 is important for the allocation of functionality to hs-unc-53/3.
  • Hs-unc-53/3 is highly expressed in brain, as shown on the Northern blots (figure 5a) .
  • FIG 5b it can be seen that Hs-unc-53/3 also is differentially expressed in different parts of the brain. Its homologues are not or weakly expressed in brain. This gives an indication that its function in directionality of cell migration and growth cone steering will be in relation to specific regions or cells of the brain.
  • Hs-unc-53/3 will be an important signal transducer or signal adapter linking signals to neuronal outgrowth, axon guidance, and formation and maintenance of synaptic connections. It seems that the function of Hs-unc- 53/3 will be associated with neuron-neuron interactions, neuronal outgrowth, neuron muscle interactions, and post-synaptic signal transduction. Furthermore, Hs-unc-53/3 may be involved in the development of cancer of neuronal origin, like neuroblastomas, or the development of tumours will have their developmental origin in the brain as some eyes diseases like retinoblastomas .
  • Hs- unc-53/3 in brain tissue can be associated with the high levels of expression which has also been observed in the spinal cord, containing neuronal tissue.
  • neuronal (axon) outgrowth and neuron-neuron connections are of importance.
  • Development of pharmacological tools acting on this pathway may lead to treatments of diseases involved in the growth and movement of neuronal cells, and the regeneration of neuronal connectivity after trauma, or the inhibition of neuronal cancers such as neuroblastomas.
  • Due to its specific expression, inhibitors and/or enhancers specific for Hs-unc-53/3 will have an advantage as a pharmaceutical compound over more general compounds acting on the Hs-unc-53 family of genes and proteins.
  • Hs-UNC-53/3 could therefore function as part of the signal transductions pathway involved in the maturation of leukocytes. Malfunction of this pathway may lead to incorrect maturation of the leukocytes and the development of autoimmune diseases such as rheumatoid arthritis and sclerosis.
  • Hs-UNC-53/3 may also play an important role in the induction and/or signalling pathway of the mechanism underlying apoptosis of leukocytes in the spleen.
  • hs-UNC-53/3 pathway Pharmaceutical methods involving the hs-UNC-53/3 pathway, which may, for example, result in an inhibition and/or enhancement of its expression may lead to treatment of these disorders.
  • hs-UNC-52/2 may have an advantage, as an inhibitor or enhancer specific for hu-unc53/3 which will act in a more specific manner.
  • the Hu-UNC-53/3 protein is also highly expressed in the ovary, where the two other human homologues are also expressed.
  • moderate to low expression of hs-unc53/3 is observed in heart, placenta, testis, stomach and adrenal gland.
  • Hs-unc- 53/3 Although the predominant transcripts of Hs-unc- 53/3 are > 9 kb, often a smear occurs that ends at with somewhat higher intensity at 5.5 - 6.5 kB. This short transcript may correspond to AB023155.
  • the Hs-unc53/3 gene is a highly regulated gene, showing strong tissue specificity and additional mechanisms of regulation which have not previously been identified in any of its known homologues. These findings may thus lead to the development of more specific inhibitors or enhancers of hs-UNC-35/3 and or of the Hs-UNC-53/3 pathway.
  • the Northern blot studies indicate that the three human unc-53s are complex transcriptional units with highly regulated tissue specificity and that transcripts of different lengths exist.
  • the second variant in Hs-unc-53/3 (fig. 2) deletes a box (MQLDNRTLPKKGLR) , which is extremely conserved (in bold) among all human unc-53s. This occurrence of this variant could indicate differentially active functional variants of Hu- unc53/3.
  • Hs-unc-53/1 has a first variant that comprises the most N-terminal portion of this conserved domain (SGSFRD) .
  • a second splice variant in Hs-unc-53/1 (AEERMOSE) lies within the highly conserved domain.
  • Another conserved spot for splice variation in human unc-53s has been found (figure 2): Hs-unc-53/1 ⁇ VYE ⁇ ; -/2 ⁇ VNE ⁇ and -/3 ⁇ NSRGSEL ⁇ . All these spliced exons are flanked by two conserved charged domains - putative nuclear localisation signals.
  • Hu-unc-53/3 has another variant (SPLVWPPKKRQNGPVIYKHSR) (fig. 2) .
  • SPLVWPPKKRQNGPVIYKHSR SPLVWPPKKRQNGPVIYKHSR
  • the RT-PCR study for Hs-unc-53/1 revealed that the most 5' -splice variant is differentially expressed in normal versus neoplastic cells/cell lines. This exon is present in 7/7 keratinocytes, HUVEC and in melanocytes but lacking in HaCat, ECV304, 2/7 melanoma and MCF-7 cells (breast carcinoma) .
  • tumourigenic endothelial line ECV304 lacks expression of Hs-unc-53/2, whereas their normal counterpart HUVEC expresses Hs-unc-53/2, suggesting gene deletion or inactivation of expression in ECV304.
  • epidermal keratinocytes and the lineage matched spontaneously transformed keratinocyte HaCaT and MCF-7 lack expression of the 5' -end of Hs-unc- 53/2, but express the 3' end (starting in or near the microtubule-binding domain) .
  • Hs-unc-53/2 can be expressed as a truncated 3' -variant in a cell-specific way.
  • splice variation of Hs-unc-53/2 appears to differ in a normal to neoplastic way: the ⁇ VNE ⁇ exon was shown to be present in all keratinocyte isolates but not in HaCaT and also melanocytes express it, but not 2/7 melanoma or MCF-7.
  • the RT-PCR studies for Hs- unc-53/3 were focussed on demonstrating expression of AB023155 in tissues other than brain. The new exon described was shown to be present in keratinocytes, HUVEC, dermal fibroblasts, melanocytes and their transformed/neoplastic variants, demonstrating its wide expression in tissues in man.
  • AA918601, AI248585, AA115014 and AA115015 are clearly homologous to the 3'-UTR of Hs- Unc-53/2 cDNA ( Figure 1(c))).
  • AA115014 (describing the same EST as AA115015) contains an alternative splice variant of the Hs-Unc53/2 gene in the 3'UTR.
  • Hs-unc-53/3 can be classified as a bona fide human unc-53. To further understand its function and in anticipation of developing pharmacological compound screening assays, Hs-unc-53/3 has been physically cloned following the method described in the experimental section and shown in figure 7a.
  • the derived Hs-unc-53/3 clones comprising full length (A to L and the 3' -half (G to L) of Hs-unc-53/3 were further engineered to form a chimera with green fluorescent protein and cloned into expression vectors appropriate for transfection of eukaryotic cells.
  • the nucleic acid and amino acid sequences of these constructs are shown in figure 7b- e.
  • the constructs were transfected into cells and scored for their effects on the F-actin cytoskeleton and binding to microtubules of mouse neuroblastoma cells N4; functions known for nematode unc-53 and human unc-53/1.
  • N4 cell transfected with a GFP fusion to the 3' -half of Hs-unc-53/3 showed pronounced filopodia and lamellipodia outgrowth, which is associated with reorganization of the F-actin cytoskeleton ( Figure 8).
  • This observation demonstrates that like nematode unc-53 and human unc- 53/1, the F-actin binding domain is not required for inducing reorganization of the F-actin cytoskeleton of N4 cells.
  • the pGI3303 encoded fusion protein does not co-localize with microtubuli but localizes to the cytoplasm of N4 cells indicating that an important domain for microtubuli association is missing in this C-terminal fragment of Hs-unc-53/3.
  • the C- terminal half of Hs-unc-53/3 (approximate KIAA0938) does not comprise the conserved microtubule binding domain.
  • N4 cells that expressed low to medium levels of the GFP fusion to full length Hs-unc- 53/3 displayed a co-localization of the GFP fusion protein with microtubules ( Figure 9) . Even the centrosomes could clearly be detected in some transfected cells. Cells expressing very low amounts of the fusion protein displayed specific microtubule (+)-end binding ( Figure 9).
  • the morphology of the pGI3305 transfected N4 cells does not clearly differ from the control transfected cells although there is a tendency towards rounding up of the pGI3305 transfected cells and filopodia outgrowth.
  • R74288 has previously been shown to be an inhibitor of nematode function in C. elegans (W096/38555) , an activity that has been confirmed in Ce-unc-53 transfected N4 cells, where only the transgene-induced effect was inhibited by R74288.
  • a stable transfection of plasmid pGI3150 was performed in the N4 neuroblastoma cell line with the lipofectamin procedure (Gibco BRL) .
  • pGI3150 expresses an eGFP protein in fusion with the C-terminal end of Hs-unc-53/1 (see Figure 15a) .
  • Compound screening assays must have a sufficiently high throughput to be relevant to drug discovery. To achieve this goal, we automated the procedure of measuring the morphological changes induced in cells following transient transfection with full length or 3' -half of Hs-unc-53/3 GFP chimeras.
  • the cell culture, transfection, fluorescence staining and microscopy procedures are performed within a 96- well plate (all-in-one) .
  • the fluorescent staining method comprises a triple fluorescent labeling procedure (1) for cell nucleic using DNA double helix intercalating dyes such as Hoechst 33342 or DAPI, (2) for transfection efficiency and expression level of the chimeric protein using GFP fluorescence and (3) for the F-actin cytoskeleton using fluorescently labeled phalloidin, a microfilament dye.
  • Chromosome 12q21.1 is a region shown to be involved in autosomal dominant, cornea plana and closed angle glaucoma (Sigler- Villanueva et al., Ophthalmic Genetics 18:55-62, 1997) . This indicates that hs-UNC-53/3 protein may be involved in eye development and thus eye diseases, such as retinoblastomas . Neuroblastoma cell line NPG and liposarcoma line WDLPS and other sarcoma lines have amplifications in this region.
  • the neuroblastoma amplification seems to be located more distal (12q24) while the liposarcoma line is located at 12q21 (Van Royal et al . , Cancer Genetics and Cytogenetics 82:151- 4, 1995).
  • Three loci related to Darier' s disease, an autosomal dominant genodermatosis disease characterized by epidermal acantholysis and dyskeratosis have been mapped in region 12q21-q24 (Wright et al . , Journal of Investigative Dermatology 103:665-8). 12q21 is also known to be a fragile site associated with the pathogenesis of non-Hodgkin' s Lymphoma (Chary-Reddy et al .
  • RH mapping is a somatic cell hybrid technique that was developed to construct high-resolution, contiguous maps of mammalian chromosomes.
  • RH mapping provides a method for ordering DNA markers spanning millions of base pairs of DNA at a resolution to easily obtained by other mapping methods.
  • sequence information available in public domain can help refine the positioning of the unc-53 genes, like in the following example.
  • the EST clones AA918601, AI248585, AA115014 and AA115015 are clearly homologous to Hs-Unc53/2 cDNA.
  • AA115014 (describing the same EST as AA115015) contains an alternative splicevariant of the Hs-Unc53/2 gene in the 3'UTR.
  • the STS was localized by analysis on the NIGMS human/rodent somatic cell hybrid panel (dbSTS id: 41891) .
  • the radiation hybrid results are summarized in Figure 13. Together these data imply that diseases or phenotypes connected to SHGC-33456 is due to the Hs-Unc53/2 gene.
  • Hs-unc53/3 has been cloned starting from a series of ESTs that were similar but not identical to Hs-unc- 53/1 or -/2.
  • the ESTs were:
  • Transformed cells carrying the EST 767735 sequence were ordered from Research Genetics. Plasmid DNA was isolated using standard protocols (Qiagen plasmid DNA isolation kit) , the sequence of the insert was determined.
  • Transformed cells carrying the cDNA clone 86459 sequence were ordered from ATCC. Plasmid DNA was isolated using standard protocols (Qiagen plasmid DNA isolation kit) , the sequence of the insert was determined. 3. Genethon cDNA clone c09a03 from the Geneexpress cDNA program.
  • Transformed cells carrying the cDNA clone c09a03 sequence were ordered from Genethon. Plasmid DNA was isolated using standard protocols (Qiagen plasmid DNA isolation kit) , the sequence of the insert was determined.
  • Marathon-Ready cDNAs (Clontech) are premade "libraries" of adaptor-ligated double-stranded cDNA ready for use as templates in RACE experiments.
  • Five ml Marathon-Ready cDNA was used as template in a regular 50 ml RACE.
  • the RACE mixture contained 1 x KlenTaq PCR buffer. 0.2 mM of each dNTP, 1 x advantage KlenTaq polymerase mix (Clontech), 0.15 mM API adaptor primer and 0.15 mM RACE gene specific primer.
  • the amplification conditions were as follows: 94°C for 30 s and 68 °C for 4 min.
  • Gene specific primer (hh3UNC53 97102702) 5'CAATCGTCTTCAGGTGTAAATGGTAACGTG; nested gene specific primer (hh3UNC53 97102703)
  • gene-specific primer (hh3UNC53 98020401) 5'AGGGAGCACTGAATGGTCCAGACCATCCTC; nested gene-specific primer (hh3UNC53 98020402)
  • 5'GCATCAGAAGACAGCATTCCTCTGAAAGTG Marathon cDNA library human placenta, human heart, human HeLa, human melanoma, human colorectal adenocarcinoma, human chronic myelogenous leukemia.
  • 5'GGATGCCGGAAGGGATGAATCAGTAAGC Marathon cDNA library: human placenta, human heart, human HeLa, human melanoma, human colorectal adenocarcinoma, human chronic myelogenous leukemia.
  • BAC DNA was prepared according to a modified Qiagen plasmid DNA procedure.
  • a primer pair was designed specifically to amplify the 5' end of the variant shown in full in figure le (primers ACTTGCTGAAACAGAGAGCTCCATG and CTTGCTGTCTTCTTTCTCCTTGGC) .
  • PCR with these primers on BAC DNA showed the presence of the genomic sequence encoding this variant in 3 out of the 4 BACs (not present in BAC 415J11) .
  • BACs containing the genomic sequence encoding the other 5' end variant of Hs-unc-53/3 as shown as the variant in figure le were identified by hybridizing the Research Genetics human DNA GAC filters with primer TGATCTTCTAGCGTGTGACTCACTG, radioactively labeled using gamma-P32-ATP and polynucleotide kinase. Positive BACs were 404F14, 450K18 and 764L15.
  • primer pairs were selected such that the ORF could be amplified in 6 overlapping fragments ranging in size from 1 to 2 kbp. Overlaps between the fragments were chosen such that they contain an endonuclease restriction enzyme recognition site suitable for cloning the full-length gen.
  • the downstream oriented primer was chosen to contain the first putative start codon (ATG) in variant 1 (the one shown in full in figure le) .
  • A-B 2229 A TCAGCTCGAGCATATGCCTGTTCTTGGGGTTGC B GGGGTGGGTCGACTTGTCAAGTGG
  • E-F 781 E CAGGTTCCTGGAGAAGAGGCATGTC
  • Primer A contains restriction sites (Xhol and nhel) suitable for final subcloning in an eukaryotic expression vector (pEGFPc3) and in a yeast-two-hybrid vector (pAS2-l), respectively.
  • PCR products were analyzed by agarose gel electrophoresis and were visualized by ethidium bromide staining. Splice variants as mentioned in figure le were observed as multiple bands on agarose gels. Single band PCR products were purified with the Qiaquick PCR purification kit, whereas multiple band PCR products were cut out from gel as individual bands and purified using the Qiaquick gel extraction kit. PCR products were cloned in pCR2.1 according to the suppliers protocol (Invitrogen) .
  • a clone was selected that missed the heart specific 22 amino acid splice variant (figure If) .
  • a Sfil-SacII linker was cloned in the BamHI site of the pCR2.1 multiple cloning site to facilitate subcloning of the full- length gene into the yeast-two-hybrid vector (pAS2-l) and the eukaryotic expression vector (pEGFPc3) , respectively.
  • the overall cloning strategy of the full-length gene is visualized in figure 7a. 7al illustrates the overlapping PCR fragments and the nomenclature of fragments and primer pairs.
  • FIG. 7a2 illustrates the assembly of the 3' half of the gene in pCR2.1.
  • Internal BamHI (I-J fragment) and Xhol (K-L fragment) sites as well as restriction sites from the multiple cloning site of pCR2.1 (as shown in the figure) were removed by side-directed mutagenesis (SDM) using the Quickchange Site-Directed mutagenesis kit (stratagene) .
  • SDM side-directed mutagenesis
  • the Notl-EcoRI G-H fragment and the EcoRI-Nhel I-Jd22 (d22 indicating that the 22 amino acid splice variant is absent) were directionally cloned in the Notl and Nhel sites of the K-L fragment clone. Multiple clones were picked and verified by DNA sequencing.
  • FIG. 7a3 illustrates the assembly of the 5' half.
  • Internal Xhol (C-D fragment) and Sfil and Xhol (E-F fragment) sites were removed by SDM. Inserts were cut out from the vectors by restriction digestion with the appropriate restriction enzymes (Xhol+Sall; Sall+Narl and Narl+BamHI, respectively) and purified from gel after agarose gel electrophoresis. The 3 fragments were ligated together, re-cut with Xhol and BamHI and separated on gel. The band of the expected size was cut out of gel, purified and cloned in front of the 3' half, opened by digestion with Xhol and BamHI (figure 7a4) . Multiple clones were picked and verified by sequencing.
  • Figure 7a illustrates the modular nature of the cloning project. For all the possible combinations of splice variation within the building block fragments, one representative clone is available. In view of functional analysis, building blocks can be exchanged easily by standard technology, either in the pCR2.1 construct or in the final eukaryotic expression or yeast-two-hybrid construct.
  • pG13303 can be used to over-express in mammalian cells or animals a fusion protein between eGFP and 1128 AA C-terminal fragment of Hs-unc-53/3 (Fig 7c) .
  • pG3305 can be used to overexpress in mammalian cells or animals a fusion protein between eGFP and the 2363 AA full length Hu- unc-53/3 (fig 7d) .
  • the Hs-unc-53/3 cDNA in pGI3303 as well as in pGI3305 contains silent mutations that introduce or remove specific restriction sites in order to be able to easily subclone different types of alternative splice variants in these vectors.
  • Genomic DNA sequencing (BAC 585E09)
  • BAC DNA was isolated from E. coli genomic clone 585E09 according to a modified Qiagen plasmid DNA preparation procedure. A shotgun library of 1920 clones was constructed at GATC (Konstanz, Germany) .
  • BAC DNA was prepared, nebulized and subcloned after end-repairing in the sequence vector pTZ19R.
  • DNA was prepared on the Biorobot 9600 (Qiagen) from 1440 clones. End sequencing reactions with Ml3 forward (TGTAAAACGACGGCCAGT) and reverse (CAGGAAACAGCTATGACC) primer were done on 768 clones. 672 additional clones were sequenced with M13 only. 5 ⁇ l DNA was used in 15 ⁇ l final reaction volume using the BigDye Terminator Ready Reaction sequencing kit. Sequencing reactions were run on MJ Research PTC200 PCR machines. Reaction products were run and analysed on PE ABI 377 DNA sequencers.
  • a Human multiple tissue Norther (MTN-1, Clontech) containing in each lane 2 mg of poly A + RNA from eight different human tissues (heart, brain, placenta, lung, liver, skeletal muscle, kidney, and pancreas) and a MTN-II human multiple tissue Northern, containing in each lane 2 mg of poly A + RNA from spleen, thymus, prostate, testis, ovary, small intestine, colon and peripheral leukocyte, were hybridized according to the manufacturer's instructions and washed out in 0. lxSSC: 0.2% SDS at 55°C.
  • MTN-1 Human multiple tissue Norther
  • RNA blot from human cancer cell lines (melanoma G361, lung carcinoma A549, colorectal adenocarcinoma SW480, Burkitt' s lymphoma Raji Leukemia Molt 4, lymphoblastic leukemia K562, HeLa S3 and promyelocytic leukemia HL60) was tested.
  • a set of cancer cell line Northern blots were probed with a 665 bp fragment of Hs-unc-53/3 amplified by using the primers 5' AGGAATTAAAATTAACGGATATTCGG and 5'AAAACTGTCCAAACTATTTTCTTCTACC.
  • HU-unc-53/3 is expressed in Melanoma G361 and lung carcinoma A549, transcripts sizes were detected of >0.5 kb.
  • No expression was detected in promyelocytic leukemia HL- 60 HeLa cell S3, chronic myelogenous leukemia K-562, leukemia MOLT-4, Burkitt' s lymphoma Raij and colorectal adenocarcinoma SW480.
  • a set of normal human tissue Northern blots were probed with a 665 bp fragment of Hs-unc-53/3 amplified by using the primers 5' AGGAATTAAAATTAACGGATATTCGG and 5' AAAACTGTCCAAACTATTTTCTTCTACC .
  • Hs-UNC-53/3 is localised to chromosome 12q21.1
  • Lymphocytes isolated from human blood were cultured in -minimal essential medium (MEM) supplemented with 10% foetal calf serum and phytohaemagglutinin (PHA) at 37°C for 68-72 hr.
  • the lymphocyte cultures were treated with BrdU (0.18mg/ml Sigma) to synchronise the cell population.
  • the synchronised cells were washed three times with serum- free medium to release the block and recultured at 37°C for 6 hr in a ⁇ -MEM with thymidine (2.5 ⁇ g/ml: Sigma) .
  • Cells were harvested and slides were made by using standard procedures including hypotonic treatment fix and air-dry.
  • a cDNA probe was biotinylated with dATP using the BRL BioNick labelling kit (15°C, 1 hr) Heng et al, 1992) .
  • the procedure for FISH detection was performed according to Heng et al . , 1992 & Heng and Tsui, 1993. Heng et al..: Proc Natl Acad Sci USA 89: 9509-9513 (1992). Heng et al . Chromosoma 102: 325-332 (1993). Briefly, slides were baked at 55°C for 1 hour. After RNase treatment, the slides were denatured in 70% formamide in 2xSSC for 2 min. at 70°C followed by dehydrated with ethanol.
  • Probes were denatured at 75°C for 5 min. in a hybridisation mix consisting of 50% formamide and 10% dextran sulphate. Probes were loaded on the denatured chromosomal slides. After over night hybridisation, slides were washed and detected as well as amplified. FISH signals and the DAPI banding pattern were recorded separately by taking photographs, and the assignment of the FISH mapping data with chromosomal bands was achieved by superimposing FISH signals with DAPI banded chromosomes (Heng et al, 1993) .
  • the hybridisation efficiency was approximately 67% for this probe (among 100 checked mitotic figures, 67 of them showed signals on one pair of the chromosomes) . Since the DAPI banding was used to identify the specific chromosome, the assignment between signal from probe and the long arm of chromosome 12 was obtained. The detailed position was further determined in the diagram based on the summary from 10 photos.
  • Radiation hybrid analysis is a PCR technique and the panels of radiation hybrid DNA are provided at a concentration of 25 ng/ ⁇ l in TE buffer suitable for these reactions. Typically, 25 ng of DNA is used in a 10 ⁇ l PCR reaction.
  • RH mapping involves the statistical analysis of several to many markers to determine the relative order of the markers with respect to one another. RH mapping can be achieved using statistical programs that will provide the best map along with a measure of the relative likelihood of one order versus another.
  • N$ neuroblastoma lines were seeded in Lab Tek chambered coverglass (Nalgene Nunc International) and transfected with pEGFP (control), pGI3303 and pGI3305 using lipofectamine (Life Technologies BRL) . After 24-48 hours, the chambered coverglasses were placed on an inverted fluorescence microscope where GFP fluorescence could be visualized in living cells. The details of this method have been described in PCT/EP96/02311.
  • Seq ID No 1 is a nucleic acid sequence of Hs unc-53/1 and lacking the nucleotides from position 2873 to 3043 shown in Fig. la.
  • Seq ID No. 2 is a nucleic acid sequence of Hs unc-53/1 and lacking the nucleotides from position 3098 to 3121 shown in Figure la.
  • Seq ID no. 3 is a nucleic acid sequence of Hs-unc-53/1 and lacking the nucleotides from position 3518 to 3526 of the sequence identified in Fig. la.
  • Seq ID No. 4 is an amino acid sequence of Hs-unc-53/1 protein and lacking the amino acids from position 958 to 1014 of the sequence identified in Fig. lb
  • Seq ID No. 5 is a amino acid sequence of Hs-unc-53/1 protein and lacking the amino acids from position 1033 to 1040 of the sequence identified in Fig. lb.
  • Seq ID No. 6 is a amino acid sequence of Hs-unc-53/1 protein and lacking the amino acids from position 1173 to 1175 of the sequence identified in Fig. lb.
  • Seq ID No. 7 is a nucleotide sequence encoding Hs- unc-53/2 and lacking the nucleotides from position 5425 to 5433 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 8 is a nucleotide sequence encoding Hs- unc-53/2 and lacking the nucleotides from position 5924 to 6024 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 9 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 1 illustrated in Fig. Ic.
  • Seq ID No. 10 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 2 illustrated in Fig. Ic.
  • Seq ID No. 11 is a nucle ⁇ ticfe " sequence encoding Hs- unc-53/2 and having the sequence of variant 3 illustrated in Fig. Ic.
  • Seq ID No. 12 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 1 illustrated in Fig. Ic. and lacking the nucleotides from position 5425 to 5433 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 13 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 1 illustrated in Fig. Ic. and lacking the nucleotides from position 5924 to S024 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 14 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 2 illustrated in Fig. Ic. and lacking the nucleotides from position 5425 to 5433 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 15 is a nucleotide sequence encoding Hs- unc-53/2 ar.d having the sequence of variant 2 illustrated in Fig. Ic. and lacking the " nucleotides from position 5924 to 6024 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 16 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 3 illustrated in Fig. Ic. and lacking the nucleotides from position 5425 to 5433 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 17 is a nucleotide sequence encoding Hs- unc-53/2 and having the sequence of variant 3 illustrated in Fig. lc._ and lacking the_ nucleotides. from position 5324 to 6024 of the sequence illustrated in Fig. Ic.
  • Seq ID No. 18 is an amino acid sequence of Hs-unc- 53/2 protein and lacking the amino acids from position 1776 to 1778 of the sequence identified in Fig. Id
  • Seq Id No. 19 is an amino acid sequence of variant 1 of Hs-unc-53/2 sequence illustrated in Fig. Id.
  • Seq Id No. 20 is an amino acid sequence of variant 2 of Hs-unc-53/2 sequence illustrated in Fig. Id.
  • Seq Id No. 21 is an amino acid sequence of variant 3 of Hs-unc-53/2 sequence illustrated in Fig. Id.
  • Seq Id No. 22 is an amino acid sequence of variant 1 of Hs-unc-53/2 sequence illustrated in Fig. Id and lacking the amino acids from position 1776 to 1778 of the sequence identified in Fig. Id.
  • Seq Id No. 23 is an amino acid sequence of variant 2 of Hs-unc-53/2 sequence illustrated in Fig. Id and lacking the amino acids from position 1776 to 1778 of the sequence identified in Fig. Id.
  • Seq Id No. 24 is an amino acid sequence of variant 3 of Hs-unc-53/2 sequence illustrated in Fig. Id and lacking the amino acids from position 1776 to 1778 of the sequence identified in Fig. Id.
  • Seq ID No. 25 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le.
  • Seq ID No. 26 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le and lacking the nucleotides from position 3795 to 4283 of the sequence identified therein.
  • Seq ID No. 27 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le and lacking the nucleotides from position 4284 to 4325 of the sequence identified therein.
  • Seq ID No. 28 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le and lacking the nucleotides from position 3795 to 4325 of the sequence identified therein.
  • Seq ID No. 29 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le and lacking the nucleotides from position 5153 to 5173 of the sequence identified.
  • Seq ID No. 30 is a nucleotide sequence encoding Hs- unc-53/3 as illustrated in Figure le and lacking the nucleotides from position 5343 to 5408 of the sequence identified.
  • Seq ID No. 31 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le.
  • Seq ID No. 32 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le and lacking the nucleotides from position 3795 to 4283 of the sequence identified therein.
  • Seq ID No. 33 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le and lacking the nucleotides from position 4284 to 4325 of the sequence identified therein.
  • Seq ID No. 34 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le and lacking the nucleotides from position 3795 to 4325 of the sequence identified therein.
  • Seq ID No. 35 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le and lacking the nucleotides from position 5153 to 5173 of the sequence identified therein.
  • Seq ID No. 36 is a nucleotide sequence encoding Hs- unc-53/3 having the sequence of variant 1 illustrated in Fig. le and lacking the nucleotides from position 5343 to 5408 of the sequence identified therein.
  • Seq ID No. 37 is an amino acid sequence of Hs-unc- 53/3 protein as identified in the sequence of Fig. If.
  • Seq ID No. 38 is an amino acid sequence of Hs-unc- 53/3 protein as identified in the sequence of Fig. If and lacking the amino acid residues from position 1326 to 1413 of the sequence identified therein.
  • Seq ID No. 39 is an amino acid sequence of Hs-unc- 53/3 protein as identified in the sequence of Fig. If and lacking the amino acid residues from position 1414 to 1427 of the sequence identified therein.
  • Seq ID No. 40 is an amino acid sequence of Hs-unc- 53/3 protein as identified in the sequence of Fig. If and lacking the amino acid residues from position 1703 to 1709 of the sequence identified therein.
  • Seq ID No. 41 is an amino acid sequence of Hs-unc- 53/3 protein as identified in the sequence of Fig. If and lacking the amino acid residues from position 1768 to 1788 of the sequence identified therein.
  • Seq ID No. 42 is an amino acid sequence of Hs-unc-53 of variant 1 identified in Figure If.
  • Seq ID No. 43 is an amino acid sequence of Hs-unc-53 of variant 1 identified in Figure If and lacking the amino acid residues from position 1326 to 1413 of the sequence identified therein.
  • Seq ID No. 44 is an amino acid sequence of Hs-unc-53 of variant 1 identified in Figure If and lacking the amino acid residues from position 1414 to 1427 of the sequence identified therein.
  • Seq ID No. 45 is an amino acid sequence of Hs-unc-53 of variant 1 identified in Figure If and lacking the amino acid residues from position 1703 to 1709 of the sequence identified therein.
  • Seq ID No. 46 is an amino acid sequence of Hs-unc-53 of variant 1 identified in Figure If and lacking the amino acid residues from position 1768 to 1788 of the sequence identified therein.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Breeding Of Plants And Reproduction By Means Of Culturing (AREA)
  • Peptides Or Proteins (AREA)

Abstract

L'invention concerne des homologues humains de la protéine UNC-53 de C. elegans et un codage de séquences d'ADN de ces homologues ou de leurs équivalents fonctionnels. L'invention concerne également des procédés d'identification de composés régulant le comportement cellulaire, de composés identifiés et de compositions pharmaceutiques les contenant, ainsi que des procédés et dosages d'identification d'états pathologiques dans lesquels ce gène ou cette protéine présente un dysfonctionnement.
EP99926511A 1998-06-03 1999-06-02 Homologue humain de la proteine unc-53 de c. elegans Withdrawn EP1092019A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9811962.1A GB9811962D0 (en) 1998-06-03 1998-06-03 Vertebrate homologue of UNC-53 protein of C.elegans
GB9811962 1998-06-03
PCT/EP1999/003848 WO1999063080A1 (fr) 1998-06-03 1999-06-02 HOMOLOGUE HUMAIN DE LA PROTEINE UNC-53 DE $i(C. ELEGANS)

Publications (1)

Publication Number Publication Date
EP1092019A1 true EP1092019A1 (fr) 2001-04-18

Family

ID=10833159

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99926511A Withdrawn EP1092019A1 (fr) 1998-06-03 1999-06-02 Homologue humain de la proteine unc-53 de c. elegans

Country Status (6)

Country Link
EP (1) EP1092019A1 (fr)
JP (1) JP2002517194A (fr)
AU (1) AU4373599A (fr)
CA (1) CA2330179A1 (fr)
GB (1) GB9811962D0 (fr)
WO (1) WO1999063080A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19908423A1 (de) * 1999-02-26 2000-08-31 Deutsches Krebsforsch An der Entwicklung des ZNS beteiligtes Protein (TP)
DE10042609A1 (de) * 2000-08-30 2002-03-28 Deutsches Krebsforsch Verwendung von T-Proteinen zur differentiellen Charakterisierung und Therapie von Verletzungen und Tumoren des Nervensystems
HK1216895A1 (zh) 2012-11-25 2016-12-09 The Regents Of The University Of California 刺激皮下脂肪形成的肽
WO2015184125A1 (fr) * 2014-05-28 2015-12-03 The Regents Of The University Of California Peptides, compositions et procédés pour stimuler l'adipogenèse sous-cutanée
CN105738607B (zh) * 2014-12-09 2018-04-13 费好义 一种筛选抗肿瘤药物的试剂盒及其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9510944D0 (en) * 1995-05-31 1995-07-26 Bogaert Thierry Assays and processes for the identification of compounds which control cell behaviour,the compounds identified and their use in the control of cell behaviour
GB9625283D0 (en) * 1996-12-04 1997-01-22 Janssen Pharmaceutica Nv Vertebrate homologues of unc-53 protein of c.elegans or functional eqivalents thereof and cdna sequences coding for said homologue

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9963080A1 *

Also Published As

Publication number Publication date
WO1999063080A1 (fr) 1999-12-09
AU4373599A (en) 1999-12-20
CA2330179A1 (fr) 1999-12-09
GB9811962D0 (en) 1998-07-29
JP2002517194A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
Liu et al. The retinoblastoma interacting zinc finger gene RIZ produces a PR domain-lacking product through an internal promoter
Bellen et al. The Drosophila couch potato protein is expressed in nuclei of peripheral neuronal precursors and shows homology to RNA-binding proteins.
AU724681B2 (en) Human genes
DE69838905T2 (de) Transkriptionsfaktor islet-brain 1 (ib1)
Xiong et al. A novel gene encoding a TIG multiple domain protein is a positional candidate for autosomal recessive polycystic kidney disease
EP3382036A1 (fr) Identification d'antigènes de surfaces pour le diagnostic et la thérapie de tumeurs
US6077685A (en) Tumor suppressor merlin and antibodies thereof
DE60027027T2 (de) Pca3 mrna in gutartigen und bösartigen prostatageweben
Kuriyama et al. Characterization and chromosomal mapping of a novel human gene, ANKHZN
EP1092019A1 (fr) Homologue humain de la proteine unc-53 de c. elegans
US5700926A (en) Molecular cloning of the anhidrotic ectodermal dysplasia gene
JP2000502246A (ja) 脊椎動物Ｄｅｌｔｅｘタンパク質、核酸および抗体ならびに関連方法および組成物
JP2001501469A (ja) 腫瘍抑制タンパク質をコードする核酸分子およびその単離方法
AU2004200142A1 (en) Human homologue of UNC-53 protein of C. elegans
Kobayashi et al. GP2/THP gene family of self-binding, GPI-anchored proteins forms a cluster at chromosome 7F1 region in mouse genome
EP0905239B1 (fr) Gène codant Afadin-1
CA2251603A1 (fr) Famille genetique associee a des deficiences neuro-sensorielles
US20030054446A1 (en) Novel retina-specific human proteins C7orf9, C12orf7, MPP4 and F379
JP2002503466A (ja) 網膜芽細胞腫タンパク質複合体および網膜芽細胞腫相互作用タンパク質
US5776762A (en) Obesity associated genes
JP2002525126A (ja) Ｔｒａｆ相互作用ｅｘｔ遺伝子ファミリーの新規遺伝子ｔｒｅｘ、並びにその診断及び治療への使用
US20040242468A1 (en) Gene involved in mineral deposition and uses thereof
WO1999029860A1 (fr) Polypeptides de type cadherine, procedes et compositions associes
JP2000512133A (ja) 多発性骨髄腫で変化した遺伝子の同定
DE602004005295T2 (de) Apoptotischer Faktor aus Plazenta

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20001208

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 20001123;LT PAYMENT 20001123;LV PAYMENT 20001123;MK PAYMENT 20001123;RO PAYMENT 20001123;SI PAYMENT 20001123

17Q First examination report despatched

Effective date: 20050323

17Q First examination report despatched

Effective date: 20050323

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070227